

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: May 28, 2021 Administrative Circular: 2021:21

**ATTN:** Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

# Part 4 – Biological Products

## **COVID-19 Vaccines**

## COVID-19 mRNA Vaccine BNT162b2 (Pfizer)

The product page has been revised as follows:

### Doses and Schedules:

The interval between dose 1 and 2 has been revised to 21 days with additional content to Footnote C to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the government of BC website. As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

Please remove page numbers: 1-5 dated May 20, 2021 Please add new page numbers: 1-5 dated May 28, 2021

#### COVID-19 mRNA Vaccine mRNA-1273 (Moderna)


The product page has been revised as follows:

#### Doses and Schedules:

The interval between dose 1 and 2 has been revised to 28 days with additional content to Footnote D to indicate that this is the authorized Health Canada schedule, however, the current interval in BC is based on vaccine supply and operational recommendations as outlined on the government of BC website. As of May 27, 2021, the recommended interval between dose 1 and 2 is 8 weeks.

Please remove page numbers: 1-4 dated May 20, 2021 Please add new page numbers: 1-4 dated May 28, 2021 Page 1 of 2





## COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)

The product page has been revised as follows:

#### Doses and Schedules:

- o The interval between dose 1 and dose 2 has been revised to 8 to 12 weeks apart.
- Footnote D has been revised to indicate that the preferred interval is 8 to 12 weeks.

#### Adverse Events:

- The onset of most cases of serious blood clots following receipt of the AstraZeneca or COVISHIELD vaccine has been revised to 4 to 28 days.
- The frequency of Thrombosis with Thrombocytopenia Syndrome following a second dose of vaccine has been added.

Please remove page numbers: 1-4 dated May 20, 2021 Please add new page numbers: 1-4 dated May 28, 2021

# COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

The product page has been revised as follows:

### Adverse Events:

 The onset of most cases of serious blood clots following receipt of the Janssen vaccine has been revised to 4 to 28 days.

Please remove page numbers: 1-4 dated May 20, 2021 Please add new page numbers: 1-4 dated May 28, 2021





# BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely.

Monika Naus MD MHSc FRCPC FACPM

**Medical Director** 

Communicable Diseases & Immunization Service

**BC** Centre for Disease Control

with bans

pc:

Provincial Health Officer

Dr. Bonnie Henry

Dr. Reka Gustafson Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer

Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong Executive Director, Public Health, Planning and Prevention, Population and Public Health Division



